New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
|
By LabMedica International staff writers Posted on 10 Jan 2025 |

Accurate platelet count testing is a significant challenge for laboratories. Inaccurate results can lead to misdiagnosis, missed diagnoses, and delayed treatment for a variety of potentially fatal conditions, including acute massive hemorrhage, coagulation disorders, infections, autoimmune diseases, and cancers. Pseudothrombocytopenia, a false low platelet count, can occur during platelet aggregation or due to improper handling of samples. It may also occur when large or giant platelets are present, which conventional methods fail to identify. As a result, test results may show low platelet levels, even though the actual count is normal. Such misdiagnoses can result in unnecessary anxiety, additional tests, and potentially inappropriate medications or transfusions. Surgical delays can also occur if procedures are postponed due to inaccurate results. On the other hand, pseudothrombocytosis, or a false high platelet count, typically occurs when red blood cell fragments or microcytes are misidentified as platelets. This can cause low platelet counts to be reported as normal or elevated, and normal counts to be misinterpreted as high. If low platelet counts are reported as normal or high, the risk of bleeding may go undetected, delaying treatment and potentially threatening the patient’s life. Additionally, normal platelet values reported as high could lead to incorrect diagnoses and inappropriate treatments.
Mindray (Shenzhen, China) has introduced a high-precision platelet counting technology designed to reduce risks that could lead to errors in cancer diagnoses. Available across Europe for the first time, this technology is supported by artificial intelligence (AI) and has been tested on hundreds of thousands of samples. The technology is intended to help laboratories perform more accurate and efficient platelet counting, a critical process in the detection of many serious diseases. It is designed to help laboratories address these challenges, improve accuracy, and meet the increasing demands placed on laboratories. The CAL 8000 Cellular Analysis Line combines platelet technologies to support high-quality reporting. This system automates platelet analysis, allowing laboratory professionals to report on aggregated samples in as little as 30 minutes, compared to the typical two-hour wait.
The cellular analysis line features PLT-H, a new platelet detection technology that uses high-precision optics and innovative algorithms to reduce interference and enhance accuracy without increasing costs. Self-de-aggregation technology, which involves heating, stirring, and disaggregation, can break down most platelet clumping caused by ethylenediaminetetraacetic acid (EDTA). Samples flagged as abnormal by Mindray’s cost-effective technology can be further analyzed with PLT-O. This fluorescent staining method provides accurate results for low platelet counts. When optical methods detect low platelet samples, the PLT-O instrument automatically boosts particle counting by eight times without needing to resample. This significantly improves the detection of low platelet counts.
Mindray’s PLT-M technology, integrated into its digital morphology analyzer, automatically estimates platelet counts through advanced morphological imaging. The technology also includes high-definition, high-speed scanning to identify platelet aggregation in samples by detecting platelets at the body, edge, and tail of blood smears. Known as PLT-Pro, this technology scans slides in under a minute—30 times more efficiently than traditional methods. Research into the effectiveness of this technology has been highly favorable, with findings on platelet counting presented by specialists from France and Poland at the 2024 International Society for Laboratory Hematology’s International Symposium on Technical Innovations in Laboratory Hematology.
“Abnormal platelet counts are sometimes a precursor to life threatening illnesses, including cancers such as leukemia or lymphoma,” said Huan Qi, Director of Clinical Research, Medical Affairs, Mindray. “Inaccurate platelet counting can lead to significant and potentially deadly consequences. Through innovative technology, we are now equipping laboratories with modern tools to enable efficient, high-quality, and cost-effective blood cell analysis. Through a combination of innovative tools, automation, and sophisticated algorithms, laboratories have the potential to enable 99.9% of samples to be reported with accurate platelet count results, without the need for manual intervention.”
“The latest developments in platelet counting technology could help a lot of people in treating hematology disorders,” added Professor Marie Christine Béné from the Faculty of Medicine at Nantes University. “We are getting more and more help from machines able to count cells with minimal supervision, alerting us and providing us with more time to spend looking after patients. Accurate evidence behind low platelet count could allow patients to have neurosurgery, or inform clinicians if patients don’t need a blood transfusion. Mindray has evidently listened to customers in the development of its latest technologies. Its disaggregation protocol and optical staining of platelets will help with productivity – reducing the time medical scientists need to spend examining low platelet counts to identify platelet clumping. Removing that process will be good for everyone – scientists, clinicians and patients.”
Related Links:
Mindray
Latest Pathology News
- Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
- First-Of-Its-Kind Test Identifies Autism Risk at Birth
- AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
- Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
- Fast Label-Free Method Identifies Aggressive Cancer Cells
- New X-Ray Method Promises Advances in Histology
- Single-Cell Profiling Technique Could Guide Early Cancer Detection
- Intraoperative Tumor Histology to Improve Cancer Surgeries
- Rapid Stool Test Could Help Pinpoint IBD Diagnosis
- AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery
- Deep Learning–Based Method Improves Cancer Diagnosis
- ADLM Updates Expert Guidance on Urine Drug Testing for Patients in Emergency Departments
- New Age-Based Blood Test Thresholds to Catch Ovarian Cancer Earlier
- Genetics and AI Improve Diagnosis of Aortic Stenosis
- AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
- Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







